Weight management with Tirzepatide in people with obesity
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by An Duc Thien Le |
Posted on March 31st, 2023
|
Tirzepatide had previously been approved by the Food and Drug Administration to manage type 2 diabetes. The agent mimics the insulinotropic effect of the naturally produced gastric inhibitory polypeptide. Since weight loss was a side effect of the medication when used to manage type 2 diabetes, Eli Lilly had sponsored a study to investigate the potential usage of tirzepatide in managing obesity.
The phase 3 clinical trial included 2539 adults whose average weight is 104.8 kg and average BMI is 38. They are experiencing diabetes type 2 or at least 1 other weight-related health condition such as hypertension, dyslipidemia, obstructive sleep apnea, or other forms of cardiovascular diseases. These study participants were randomly assigned to receive placebo or 3 different doses of tirzepatide: 5 mg, 10 mg, and 15 mg. The treatment was administered subcutaneously once per week for 72 weeks. Compared to the placebo group, who experienced a -3.1% change in body weight from baseline, tirzepatide significantly reduced the body weight by 15 to 21%, with the highest dose of 15 mg produced the most significant effect. In addition, tirzepatide helps significantly improve other cardiometabolic parameters such as blood pressure, fasting insulin, triglyceride, and cholesterol. Due to side effects, between 4% to 7% of the trial population had to discontinue their treatment. Gastrointestinal events such as nausea, vomiting, diarrhea, constipation, and dyspepsia are the most common adverse events, but the severity is relatively mild and moderate.
The phase 3 clinical trial included 2539 adults whose average weight is 104.8 kg and average BMI is 38. They are experiencing diabetes type 2 or at least 1 other weight-related health condition such as hypertension, dyslipidemia, obstructive sleep apnea, or other forms of cardiovascular diseases. These study participants were randomly assigned to receive placebo or 3 different doses of tirzepatide: 5 mg, 10 mg, and 15 mg. The treatment was administered subcutaneously once per week for 72 weeks. Compared to the placebo group, who experienced a -3.1% change in body weight from baseline, tirzepatide significantly reduced the body weight by 15 to 21%, with the highest dose of 15 mg produced the most significant effect. In addition, tirzepatide helps significantly improve other cardiometabolic parameters such as blood pressure, fasting insulin, triglyceride, and cholesterol. Due to side effects, between 4% to 7% of the trial population had to discontinue their treatment. Gastrointestinal events such as nausea, vomiting, diarrhea, constipation, and dyspepsia are the most common adverse events, but the severity is relatively mild and moderate.